Gaucher Disease, Type 3 Clinical Trials

16 clinical trials for Gaucher Disease, Type 3 across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3) — RECRUITING
• PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders) — RECRUITING · PHASE1
• Effect of Enzyme Replacement Therapy on Cardiac Function in Children With Gaucher Disease Type 3 — RECRUITING
• A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLEBLIND, DOUBLE-DUMMY, ACTIVE-COMPARATOR STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VENGLUSTAT IN ADULT AND PEDIATRIC PATIENTS WITH GAUCHER DISEASE TYPE 3 (GD3) WHO HAVE REACHED THERAPEUTIC GOALS WITH ENZYME REPLACEMENT THERAPY (ERT) — RECRUITING · PHASE3
• Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3) — NOT_YET_RECRUITING · PHASE2
• Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of VGN-R08b in Patients With Type III Gaucher's Disease — NOT_YET_RECRUITING · PHASE1
• High-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3) — TERMINATED · NA
• A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease — COMPLETED · PHASE4
• Effectiveness of ambroxol in children and adults with Gaucher disease 3: n-of-1 series — TERMINATED · PHASE3
• An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3 — WITHDRAWN · PHASE2
• Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3 — TERMINATED · PHASE2
• Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease — OTHER · PHASE1
• Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease — COMPLETED · PHASE1
• A THREE-PART STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VENGLUSTAT IN COMBINATION WITH CEREZYME IN ADULT AND PEDIATRIC PATIENTS WITH GAUCHER DISEASE TYPE 3 (GD3) WITH OPEN-LABEL LONG-TERM TREATMENT — NOT_YET_RECRUITING
• The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease — WITHDRAWN · PHASE4

Refine this search